Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Patisiran - Alnylam Pharmaceuticals

Drug Profile

Patisiran - Alnylam Pharmaceuticals

Alternative Names: ALN-18328; ALN-TTR02; GENZ-438027; ONPATTRO; Onpattro; Patisiran sodium - Alnylam Pharmaceuticals; patisiran-LNP; SAR-438037

Latest Information Update: 06 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action Prealbumin expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid polyneuropathy; Amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Amyloid polyneuropathy; Amyloidosis

Most Recent Events

  • 30 Apr 2024 Alnylam Pharmaceuticals expands its agreement with Medison Pharma to commercialise Patisiran, in additional Latin America and APAC markets including Australia
  • 09 Oct 2023 Alnylam Therapeutics receives complete response letter from the US FDA for patisiran for Cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis
  • 13 Sep 2023 Alnylam Pharmaceuticals announces positive outcome of the US FDA CRDAC meeting for sNDA for patisiran
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top